Drugs / TAK-583
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00760955 | Sep 2006 → Feb 2008 | diabetic polyneuropathy | Takeda | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00377598 | Oct 2006 → Feb 2008 | postherpetic neuralgia | Takeda | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-583 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00377598 ↗ |
| Route | Oral | “TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks” NCT00377598 ↗ |